List of works - Anna M Eiring

A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia

scientific article

A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia

scientific article published on 08 March 2016

Activation and maturation of alloreactive CD4-independent, CD8 cytolytic T cells

scientific article published on 04 August 2006

Advances in the treatment of chronic myeloid leukemia

scientific article

Age-related mutations and chronic myelomonocytic leukemia.

scientific article published on 09 December 2015

Alloreactive (CD4-Independent) CD8+ T cells jeopardize long-term survival of intrahepatic islet allografts.

scientific article

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

scientific article published on 14 August 2014

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships

scientific article published on 5 December 2012

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.

scientific article

CD4+ T-cell-dependent immune damage of liver parenchymal cells is mediated by alloantibody

scientific article published on 01 August 2005

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia

scientific article

Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells

scientific article published on 24 January 2020

Critical role for CD8 T cells in allograft acceptance induced by DST and CD40/CD154 costimulatory blockade.

scientific article published in July 2004

Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms

scientific article published on 14 May 2020

Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities

scientific article published on 30 March 2016

Energy metabolism and drug response in myeloid leukaemic stem cells

scientific article published on 24 June 2019

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

scientific article

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis

scientific article

Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.

scientific article

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia

scientific article published on 25 October 2012

Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm

scientific article published on 24 April 2015

Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis

scientific article published on 18 December 2018

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

scientific article published on 03 September 2013

Pushing the limits of targeted therapy in chronic myeloid leukaemia.

scientific article published on 24 July 2012

Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.

scientific article published on 02 August 2016

Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia

scientific article

The new role of microRNAs in cancer.

scientific article published in August 2010

What challenges remain in chronic myeloid leukemia research?

scientific article published on August 2013

Zebrafish screen identifies novel compound with selective toxicity against leukemia.

scientific article

miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response

scientific article

miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts

scientific article

shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.

scientific article

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.

scientific article

List of works by Anna M Eiring

A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia

A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Activation and maturation of alloreactive CD4-independent, CD8 cytolytic T cells

Advances in the treatment of chronic myeloid leukemia

Age-related mutations and chronic myelomonocytic leukemia.

Alloreactive (CD4-Independent) CD8+ T cells jeopardize long-term survival of intrahepatic islet allografts.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.

CD4+ T-cell-dependent immune damage of liver parenchymal cells is mediated by alloantibody

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia

Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells

Critical role for CD8 T cells in allograft acceptance induced by DST and CD40/CD154 costimulatory blockade.

Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms

Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities

Energy metabolism and drug response in myeloid leukaemic stem cells

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis

Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia

Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm

Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

Pushing the limits of targeted therapy in chronic myeloid leukaemia.

Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.

Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia

The new role of microRNAs in cancer.

What challenges remain in chronic myeloid leukemia research?

Zebrafish screen identifies novel compound with selective toxicity against leukemia.

miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response

miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts

shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.